How do nasal peptides actually bypass the blood-brain barrier?

Why nasal delivery exists at all

Evidence tier: 4 — Pharmacology overview of route limitations; mechanistic, with established peptide-delivery literature underlying.

Most peptide drugs are administered by injection because peptides face three structural problems as oral medications: stomach acid degrades them, the intestinal epithelium doesn't let them through efficiently, and even when absorbed they're rapidly cleared. The injection route bypasses all three but introduces its own problems — patient acceptance, sterility, infrastructure.

Nasal delivery is the third major route, and for a specific class of indications it's better than either injection or oral. The reason is anatomical: the nasal cavity has direct neural connections to the central nervous system through two pathways — the olfactory and trigeminal nerves — that bypass the blood-brain barrier entirely. For peptides whose target is in the brain, this is a substantial advantage.

The neuropeptide pillar (Semax, Selank, Cerebrolysin, Dihexa, P21) is almost universally formulated as nasal sprays for this reason. Sexual-health peptides where central action matters (PT-141, oxytocin) increasingly have nasal options. Even some growth-hormone peptides use intranasal protocols where compliance and convenience trump injection efficiency.

This article covers the actual anatomy, the bioavailability data, the formulation considerations, and where nasal delivery does and doesn't make sense.

The two nose-to-brain pathways

Evidence tier: 2 — Olfactory and trigeminal nose-to-brain mechanisms documented in human and rodent tracer studies (Dhuria 2010, Thorne 2004).

The olfactory pathway runs from the upper nasal cavity through the cribriform plate (a perforated bone separating nose and brain) to the olfactory bulb in the brain. Olfactory receptor neurons have their dendrites in the nasal mucosa and their axons running directly into the CNS. Peptides absorbed by this route can reach the olfactory bulb, then diffuse into adjacent brain regions, within 15-30 minutes.

The capacity is limited — the olfactory mucosa covers maybe 10cm² of the upper nasal cavity, accounting for ~5% of total nasal surface area. Drug deposition into this specific area requires careful spray-device design and head positioning during administration.

The trigeminal pathway runs through the trigeminal nerve, which has terminal branches throughout the nasal cavity (not just the olfactory area). Peptides taken up by trigeminal nerve endings can travel along the axons to brainstem nuclei (pons, medulla), then distribute more broadly. The trigeminal pathway has higher capacity than the olfactory but slower CNS distribution.

Both pathways together: a meaningful fraction of an intranasally administered neuropeptide reaches the CNS within 15-30 minutes, bypassing the blood-brain barrier and avoiding first-pass liver metabolism. The exact bioavailability varies by molecule and formulation but typically lands in the 5-30% range for CNS-targeted bioavailability.

Bioavailability — what the numbers actually look like

Evidence tier: 2 — Published bioavailability ranges for insulin, oxytocin, calcitonin from clinical PK studies; Semax/Selank values are working estimates.

Different peptides achieve different nasal-route bioavailability profiles. Representative published data:

• Insulin (intranasal experimental): ~10-20% systemic bioavailability vs subcutaneous
• Oxytocin nasal: ~5-15% systemic bioavailability; CNS distribution unclear
• Calcitonin (older nasal indication): ~3% systemic bioavailability — low
• Semax / Selank: published data is limited, but ~10-20% CNS-targeted bioavailability is the working estimate
• Sumatriptan (small molecule, not peptide): ~15% nasal bioavailability — useful comparison

The "10-20%" range that recurs is meaningful but small compared to injection (~80-100% bioavailability). The trade-off: nasal route delivers less drug but delivers it preferentially to the CNS, which is where the action is for neuropeptides.

For peripheral indications (where action is in liver, gut, or muscle rather than brain), nasal route's lower systemic bioavailability is a disadvantage. For CNS indications, the route's CNS-targeting is an advantage that compensates for lower total bioavailability.

Formulation factors that actually matter

Evidence tier: 4 — Formulation principles from drug-delivery literature; device geometry, excipients, pH, and droplet-size effects mechanistic.

Three factors substantially affect intranasal peptide bioavailability:

Spray device geometry. Standard pump sprays deposit primarily on the lower nasal turbinate (high-volume, low-CNS-uptake area). Specialized devices that deposit higher in the nasal cavity (closer to the olfactory mucosa) can substantially improve CNS-targeted bioavailability. The Optinose-style "breath-powered" devices and some POD designs target the upper nasal cavity better than standard pump sprays.

Excipient enhancers. Permeation enhancers like cyclodextrins, chitosan, and certain phospholipids can increase mucosal absorption 2-5x. The trade-off is mucosal irritation with chronic use.

pH and osmolarity. The nasal mucosa is sensitive to formulation chemistry. pH 5.5-7 and osmolarity close to physiologic (280-330 mOsm/kg) are optimal. Outside these ranges, mucosal irritation reduces patient compliance and can damage the absorptive surface.

Spray volume and droplet size. Volumes >100 µL per nostril per dose tend to cause runoff (drug literally drips out of the nose without absorbing). Droplet size 30-100 µm is optimal — finer aerosols deposit too low in the airway, larger droplets too much in the front of the nose.

For DIY-formulated nasal peptides (a real practice in the peptide community), most home preparations miss these specifications, resulting in substantially lower-than-claimed bioavailability and higher mucosal irritation. Pharmaceutical-grade compounded nasal preparations from licensed pharmacies meet most or all of these specifications.

The peptides where nasal makes sense

Evidence tier: 5 — Editorial mapping of route-to-indication based on mechanism; not a single comparative trial claim.

Strongest case for nasal route:

• Cognitive peptides (Semax, Selank, Cerebrolysin, P21, Dihexa) — CNS target, BBB bypass needed, fast onset matters
• Oxytocin — central action for social bonding, peripheral action mostly unwanted
• PT-141 — central melanocortin receptor activation; nasal route is being developed as alternative to injection
• Insulin (experimental for cognitive indication) — nose-to-brain insulin for Alzheimer's research, distinct from peripheral diabetes use

Less appropriate for nasal:

• GLP-1s (semaglutide, tirzepatide) — peripheral action in pancreas, GI tract, and adipose tissue; CNS-targeting unwanted
• Recovery peptides (BPC-157, TB-500, GHK-Cu) — local tissue action at injury site; injection or topical preferred
• Growth hormone secretagogues (Sermorelin, CJC, Ipa) — peripheral pituitary action; injection is the standard

What patients should actually expect from nasal protocols

Evidence tier: 4 — Pharmacokinetic expectations grounded in published nasal-delivery PK data; patient-experience descriptors are observational.

Practical expectations that match the underlying pharmacology:

Onset: 15-30 minutes for CNS-targeted action via the olfactory and trigeminal pathways. Faster than oral peptide formulations, comparable to subcutaneous injection for CNS indications.

Duration: Typically 3-6 hours per dose for short-half-life peptides like Semax and Selank. Longer for some larger molecules. Multiple daily doses are common for daily-use protocols.

Reliability: Less consistent than injection. Variability comes from inconsistent device technique, head positioning, mucosal hydration, and individual nasal anatomy. Patients often find some days produce stronger response than others.

Side effects: Mostly mucosal — occasional rhinitis, mild nasal irritation, occasional headache. Substantially milder side-effect profile than injectable equivalents for the same molecules.

Compliance: Higher than injectable for most patients. The nose-to-spray-bottle-to-back-to-life sequence is meaningfully more friction-free than subcutaneous injection, which matters for daily-use protocols.

Common technique mistakes

Evidence tier: 5 — Patient-education content from drug-delivery handling literature; mechanically obvious but not RCT-derived.

Things that reduce nasal-peptide effectiveness:

• Tilting head back during administration (drug runs down throat instead of depositing in upper nasal cavity)
• Sniffing forcefully after administration (pushes drug too far back into the throat)
• Using more than one spray per nostril without waiting (causes runoff; second dose doesn't add to first)
• Blowing nose immediately after administration (literally removes the drug)
• Using during nasal congestion (mucus blocks the absorptive surface)

Optimal technique: head slightly forward, gentle insertion of nozzle into nostril without pointing toward septum, slow inhalation as you spray, brief breath-hold after, no blowing nose for at least 15 minutes.

Regulatory context

Evidence tier: 5 — Regulatory-process section describing access pathways; no clinical evidence claim made.

Most cognitive nasal peptides (Semax, Selank, Cerebrolysin, P21, Dihexa) are research-only in the US. PT-141 is FDA-approved as Vyleesi but only as injection; nasal is compounded off-label. Oxytocin nasal is FDA-approved for some indications.

Patient access for nasal peptides follows the same pathways as other peptide categories: 503A compounding with documented medical necessity, telehealth provider partnerships, or international sourcing.

The July 23, 2026 PCAC ruling will affect compounding access for several of these molecules. See the PCAC July 2026 page for status updates.

What we'll be tracking

Evidence tier: 5 — Editorial maintenance commitment; no clinical evidence claim made.

Article updates when: - New nasal-delivery device approvals (Optinose-style or improved POD designs) - Bioavailability comparison studies between standard pump and upper-nasal-targeted devices - Phase 2/3 readouts for intranasal insulin (Alzheimer's research) - Major changes to intranasal PT-141 development - New mucosal permeation-enhancer formulations with reduced irritation

For ongoing context, see the Cognitive pillar, Semax fact box, and Selank fact box.

References

• Lochhead JJ, Thorne RG. 2012. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. PMID 22119441
• Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. 2002. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. PMID 11992114
• Dhuria SV, Hanson LR, Frey WH 2nd. 2010. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. PMID 19877171
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. PMID 15262337

Limitations

Intranasal protocols should not be used in patients with active rhinosinusitis, structural nasal abnormalities (post-surgical septum, large polyps), recurrent epistaxis, or known hypersensitivity to common excipients (chitosan, benzalkonium chloride). Pregnant or nursing patients should not use research-only neuropeptide nasal sprays without specialist supervision. Children and adolescents are out of scope, as nasal anatomy and absorptive surface differ meaningfully from adults. Patients with chronic allergic rhinitis on inhaled steroids should discuss timing with their prescriber to avoid mucosal interaction.

The cited evidence cannot tell us actual CNS-targeted bioavailability for most community-prescribed neuropeptides at the patient level — most published values come from rodent tracer studies or small human cohorts. Long-term mucosal safety data for chronic daily nasal-peptide use is also thin, and head-to-head comparisons between standard pump devices and upper-nasal-targeted devices are rare in the peer-reviewed literature.

We would change our framing on three signals: a published bioavailability comparison between device classes for a specific neuropeptide, FDA action on PCAC compounding outcomes affecting nasal availability, or new mucosal-toxicity data from chronic-use cohorts.